TOPICAL COMPOSITIONS FOR OPHTHALMIC AND OTIC USE

FIELD OF THE INVENTION

The present invention relates to topical compositions of lipoglycopeptides and pharmaceutically acceptable excipients. The lipoglycopeptides of the present invention may be selected from Telavancin, Dalbavancin and Oritavancin. The compositions of the present invention may additionally contain anti- inflammatory agents. The compositions can be used to treat patients suffering from eye and ear infections, particularly those resistant to conventionally used ophthalmic and otic antibiotics.

BACKGROUND

Telavancin hydrochloride or N3"-[2-(decylamino)ethyl]-29-[[(phosphono-methyl)- ami no] -methyl]- hydrochloride is a lipoglycopeptide antibacterial that is a synthetic derivative of vancomyci n and is represented by formula:

Telavancin (Vibactiv÷ ) was first approved in US for complicated skin and skin structure infections(cSSSI) and Hospital -acquired and Ventilator-associated bacterial pneumonia in US 6,635,618 discloses Telavancin as novel phosphonate derivative of glycopeptide for effective anti- bacterial use. The compositions of Telavancin are described for oral, parenteral and transdermal use.

US 6,858,584 & US 8,158,580 disclose pharmaceutical compositions and specifically detail the parenteral compositions.

US 6,872,701, US 7,268,971, US 7,008,923, US 7,208,471, US 7,351,691, US 7,700,550 & US 8,101,575 disclose oral, parenteral, rectal and transdermal preparation of Telavancin for treating bacterial infections.

Dalbavancin or 5,31-dichloro-38-de(methoxycarbonyl)-7-demethyl-19-deoxy-56- 0[2- deoxy-2-[(10- methyl undecanoyl)ami no]-<f-D-gl ucopyranuronosyl]-38-[[3- (di methyl ami no) propyl] carbamoyl]-42-0- -D-mannopyranosyl-15-N-methyl(ristomycin A aglycone) hydrochloride is lipoglycopeptide synthesized from a fermentation product of Nonomuraea species and is a mixture of five closely related active homologs (Ao, Ai, Bo, Bi, and B ₂ ). Dalbavanci n is represented by formula:

avanciii ¾

A¾ CB(C¾>, K

■A: ■.· ^■ ; ^■ < >■■ ^■ : :i, ^■ H,

CH,CH(CH,¾ K

B, C¾ :H ₂ C¾eH, H

B; C¾CH(CH _> )> CK; Dalbavancin (DA LVA NC E÷ ) is approved for acute bacterial ski n and skin structure i nfecti ons (A BSSSI) i n year 2014 as powder for i ntravenous admi ni strati on (500 mg base).

US 5,750,509 discloses Dalbavancin as amine derivative of glycopeptide for the treatment of bacterial infections.

US 6,900,175 describes a method of treating skin and soft tissue infection using Dal bavanci n. T he i nventi on di scl oses that the composi ti ons are admi ni stered by parenteral , e.g., intravenous or intramuscular, routes.

US 7,115,564 & US 7,119,061 describe a reconstitutable parenteral dosage form for Dalbavancin, which comprises Dalbavancin along with mannitol and lactose which act as stabi I i zers f or the f ormul ati on.

US 8,143,212 discloses method for treatment of bacterial infection by administering initial and subsequent doses of Dalbavancin. The compositions of this invention are lyophilized powders for parenteral use whi ch are to be reconstituted at the ti me of admi nistrati on,

Oritavanci n or [4_R]-22-0-(3-ami no-2,3,6-trideoxy-3-C-methyl- -Larabino- hexopyranosyl)-N3 ^"" -[(4 ^" -chloro[1,1 ^" -biphenyl]-4-yl)methyl] vancomycin phosphate is a semisynthetic lipoglycopeptide antibacterial drug represented by formula :

Oritavanci n (OR BACTIV÷ ) was first approved for marketing in US for acute bacterial skin and skin structure infections (ABSSSI) in 2014. It is available as powder for intravenous administration (400 mg base/vial). US 5,840,684 describe semisynthetic glycopeptide derivative compounds, including Oritavanci n having activity against wide variety of gram positive bacteria including vancomycin resistant strains. Pharmaceutical compositions disclosed are oral and parenteral. The patent discloses that Oritavancin can be admixed with conventional pharmaceutical carriers and excipients and used in the form of tablets, capsules, elixirs, suspensions, syrups, wafers, and the like. The patent discloses intramuscular and intravenous compositions as examples for parenteral. Working examples disclose specific oral formulations like capsule, suspension and tablet

US 8,420,592 discloses the method of use of Oritavancin for the treatment of complicated skin and skin structure infection (cSSSI). The patent discloses that the compositions are administered by parenteral or oral route.

E ye i nf ecti ons are resul t of i nvasi on of bacteri a, fungi and vi ruses. M ost commonly i nf ected eye tissues include cornea and conjunctiva. Inflammation is a usual manifestation of all ophthalmic and otic infections. Although the ophthalmic and otic infections are associated with a small number of bacteria; the rates of resistance to available antibiotics are rising and differ from strain to strain. Ophthalmic infections due to Methiciliin Resistant Staphylococcus (MRS) strains are becoming increasingly prevalent in United States M RS strai ns are responsible for over 30% of serious ophthalmic infections, it isworth noting that over 80% of these M RS strains are resistant to all fluoroquinolones, a class of antibiotics used by ophthalmologists worldwide. Apart from fluoroquinolones, these strains exhibit resistant to synthetic penicillins (methiciliin, oxaci llin, naficillin, cioxaciiiin, did oxacillin and amoxicillin) and cephalosporins. Conjunctivitis is the most commonly reported manifestation of Methicili in Resistant Staphylococcus aureus (MRSA). Conjunctivitis is an infection of outermost layer of the sclera of the eye and the inner surface of the eyelid. The other conditions include MRSA infectious scieritis, M RSA keratitis, M RSA dacryocystitis, preseptai cellulitis, corneal ulcers, endophthalmitis; orbital cel lulitis; blebitis; blepharoconjuctivitis, postoperative MRSA infection. Usually reported ear infections include otitis externa and otitis media. Ruptured tympanic membrane or surgical procedures I ike tympanostomy risk the middle ear to infections. Inflammation is a common manifestation of ophthalmic and otic i nfections. Glucocorticoids are generally used in combination with antibiotics to treat inflammation associated with eye or ear infections. The glucocorticoids, however, are associated with serious side effects e.g., diabetes, suppression of the hypothalamic- pituitary-adrenal axis, osteoporosi s etc. G I ucocorti coi ds are frequently used by ophthal mol ogi sts for i ndi cati ons which include conjunctivitis, keratitis, scleritis and post-operative management. Adverse effects on eyes specifically include cataract glaucoma, retinal emboli and maculopathy. Corticosteroids may induce ocular hypertension and glaucoma and pose serious risks after local or systemic administration. Improper use of topical corticosteroid in presence of corneal infections may lead to ocular morbidity. Ocular complications of local administration of corticosteroids include ocular surface epithelial toxicity, delayed epithelial healing, reduced wound strength, keratocyte apoptosis, corneal deposits, exacerbation of microbial infection, reactivation of herpes simplex keratitis, crystalline keratopathy, corticosteroid- induced ocular hypertension/glaucoma, corticosteroid- induced posterior subcapsular cataract, lid ptosis, dilated pupil extraocular muscle imbalance, orbital fat atrophy, intraocular vascular occlusion/haemorrhage, accidental i ntraocular penetration, systemic absorption, systemic glucocorticoid suppression.

Semisynthetic lipoglycopeptides like Telavancin, Dalbavanci n and Oritavancin promise the treatment of patients with infections caused by multi-drug-resistant Gram-positive pathogens. These compounds i nhibit the synthesis of peptidoglycan, the major structural component of the bacterial cell wall. Moreover, these compounds are capable of inhibiting cell wall biosynthesis even i n those cases where peptidoglycan is altered, thereby making them useful for treating Vancomycin Resistant Staphylococcus aureus (V RSA) strains. These compounds have shown efficacy against various Methicill in Resistant Staphylococcus (MRS) strains. However, as discussed earlier, these antibiotics are currently approved as parenteral compositions for skin related conditions.

E mergence of infections resistant to conventional ophthalmic and otic antibiotics is a serious issue. T herefore, there exists a need for safe and effective compositions for management of ophthalmic and otic infections which address the issue of antibiotic resistance. Although, various other antibiotics are well known for treating ophthalmic and otic infections, there is a need in the art for ophthalmic and otic compositions of lipoglycopeptides like Telavancin, Dalbavancin and Oritavancin which are active against the strains resistant to currently used antibiotics. Moreover, there is a need for safe and efficacious alternatives to glucocorticoids in treatment of inflammation associated with such infections. Therefore, it will be desirable to provide topical compositions of lipoglycopeptides like Telavanci n, Dalbavancin and Oritavancin for ophthalmic and otic therapy. Further, it will be more desirable to provide topical compositions of these antibiotics which wi ll also alleviate the inflammatory manifestations of the infection and sti I I be devoi d of si de- effects of gl ucocorti coi ds.

SU M MA RY OF T H E INV E NTIO N

Accordingly, the invention is based on topical compositions of lipoglycopeptide. The compositions of the present invention can be used to treat ophthalmic and otic infections and can be used prophylactically in post- operative management or in cases of ophthalmologic or otic trauma.

The invention relates to topical compositions of lipoglycopeptides selected from the group consisti ng of Telavancin, Dalbavancin and Oritavancin for treating the infections of eye and ear.

The compositions of the present invention deal with inflammation associated with eye and ear i nfections by additionally providing NSAID agents in combination with lipoglycopeptide antibiotics, thereby preventing the harmful side-effects of glucocorticoids.

The topical compositions of the invention comprise the lipoglycopeptides in an amount of about 0.001 ^" 5% w/v.

The topical compositions of the invention comprise the lipoglycopeptides in an amount of about 0.01 - 50 mg.

The compositions of the invention can be used to treat a variety of ophthalmic and otic infections, including those occurri ng due to bacterial strains resistant to conventionally used antibiotics. O BJ E CTIV E O F T H E INV E NT IO N

The main objective of the invention is to provide topical compositions comprising lipoglycopeptides and one or more pharmaceutically acceptable exci pients.

Another objective of the invention is to provide topical compositions comprising lipoglycopeptides, one or more non-steroidal anti -inflammatory agent (NSA ID) and one or more pharmaceutical ly acceptable excipients.

It is an objective of the invention to provide topical compositions comprising I i pogly copepti de for treati ng ophthal mi c and oti c i nf ecti ons.

It is an objective of the invention to provide topical compositions comprising lipoglycopeptide and one or more NSAID agent(s) for treating ophthalmic and otic infections.

It is an objective of the invention is to provide topical compositions of Telavancin and one or more pharmaceutically acceptable excipients.

It is an objective of the invention is to provide topical compositions of Dalbavancin and one or more pharmaceutically acceptable excipients.

It is an objective of the invention is to provide topical compositions of Oritavancin and one or more pharmaceutically acceptable excipients.

Still another objective of the present invention is to provide topical compositions comprising lipoglycopeptide selected from the group consisting of Telavancin, Dalbavancin and Oritavancin, one or more NSAID agent and one or more pharmaceutically acceptabl e exci pi ents.

In yet another objective the invention provides topical compositions of lipoglycopeptides i n an amount of about 0.001 ^" 5%w/v.

In yet another objective the invention provides topical compositions of lipoglycopeptides i n an amount of about 0.01 to 50 nrg. DE TAIL E D DE SC R IPT ION O F T H E I NV E NT IO N

As used herein, the term ^" li poglycopeptide _, encompass Telavancin, Dalbavancin or Oritavanci n.

As used herein, ^" Telavancin _, , ^" Dalbavancin _, or Oritavancin _, encompass free base, pharmaceutically acceptable salts, pharmacologically active metabolites thereof and their pharmaceutically acceptable salts, hydrates, its enantiomers or its racemates, unless otherwise noted.

The compositions of the invention may contain anti-inflammatory agents. The antiinflammatory agents preferred in the present invention are non-steroidal anti- inflammatory agents (NSAIDs). NSAIDs which can be employed include without limitation Ketorolac, Bromfenac, Diclofenac, Flurbiprofen, Nepafenac free base, pharmaceutically acceptable salts, pharmacologically active metabolites hydrates, its enantiomers or its racemates unless otherwi se noted. T he concentrati ons of N S A I D s wi 11 depend on the actual agent used i n the composition. The concentrations that can be employed are sufficient to reduce i nf I ammati on after topi cal appl i cati on. T he N S A I D s can be used i n the concentrati on range of 0.001% to 5% w/w.

The i nvention provides topical compositions containing lipoglycopeptide antibiotics. L ipoglycopeptide antibiotics are selected from the group consisting of Telavancin, Dalbavancin and Oritavancin, which may optionally contain NSAIDs. Accordingly, the invention provides solutions, in-situ gels, lyophilized powders, liposomal compositions, emulsions, micro-emulsions dispersion, suspensions and nano-suspensions. The compositions of the invention can be used in treatment of eye or ear infections.

A s an embodi ment of the present i nventi on, the composi ti ons compri si ng I i pogl ycopepti de, optionally containing an NSAID are solutions for instilling in the eye or ear. Solutions further include excipients like buffering agents, chelating agents, preservatives, tonicity agents, solvents and combinations thereof.

Another embodiment of the present invention includes lyophilized powders of lipoglycopeptides, optionally comprises an NSAID. These powders can be reconstituted with suitable solvent preferably water for injection before administration. The powders of the invention are prepared by lyophilization processes well-known in the art. As a further embodiment the powders after reconstitution may form a solution, dispersion, nano- suspension, micro- emulsion or liposomes for administration in eye or ear.

The compositions prepared by reconstituting powders may form in-situ gel after administration. As an embodiment the ocular residence time of the lipoglycopeptide compositions of the invention is improved by in-situ gelling systems. It is an embodiment of the present invention to provide in-situ gels or phase transition systems which are in the liquid form duri ng i nsti 11 ati on but gel orsolidify in the cul -de- sac subsequent to i nsti 11 ati on. This phase transition from liquid to solid or semi -sol id form is triggered by variety of factors whi ch i ncl ude pH of the tears, el ectrolytes present i n the tears or surface temperature of the eye. Accordingly, it is embodiment of the present invention to include exci pients whi ch are responsi bl e for i n-si tu gel I i ng of composi ti ons of I i pogly copepti des sel ected form the group consisting of Telavancin, Oritavancin and Dalbavancin, which may optionally include NSAID(s).

Sol-gel transition is triggered by change i n surrounding temperature in thermo-reversible gels. The ideal critical temperature range for such systems is ambient and physiological temperature. The hydrogel gels are classified into three types based on the critical temperature as negative temperature sensitive, positive temperature sensitive and thermal ly reversi ble hydrogels. Negative temperature sensitive hydrogels have a lower critical solution temperature (LCST) whereas positive temperature sensitive gels have upper critical solution temperature (UCST). LCST polymers contract on heating above critical temperature and UCST polymers contract upon cooling below critical temperature. LCST polymers having critical temperature between ambient and physiologic temperature are preferred. Thermoreversible gels at elevated temperatures form random coils and upon cool ing form a partial helix which is responsi ble for continuous network formation. In an embodiment of the present invention, temperature sensitive gelling polymers are incorporated in the compositions of I i pogly copepti des selected form the group consisting of Telavancin, Oritavancin and Dalbavancin which may optionally include NSAIDs. Such polymers without limitation include Poloxamer, cellulose derivative: methyl cellulose (MC), hydroxy propyl methyl cellulose (HPMC), ethyl (hydroxyethyl) cellulose, xyloglucan and others.

Ionic strength is other i mportant factor in gel ling of polymers. A change in ionic strength acts as a trigger for gelation. The rate of gelation is influenced by osmotic gradient across the gel surface. The osmolality of the solution, therefore, affects the rate of sol-gel transition, typical ly i n eye. T he aqueous polymer sol utions form a gel in presence of mono or divalent cations present in tear fluids. The presence of Na, Mg and Ca cations and other electrolytes are responsible for triggering gelation in conjunctival cul-de-sac. It is an embodiment of the present invention to provide pharmaceutical compositions of lipoglycopeptides selected form the group consisting of Telavancin, Oritavancin and Dalbavancin which optional ly incl ude NSAIDs and polymers which gel in response to changes in ionic strength. Examples of such polymers without being bound to any limitations as such i nclude Gellan gum, alginates, chitosan, fibrin, collagen, gelatin, hyaluronic acid, dextran, hydroxyethyl methacryate (H E MA), N-(2-hydroxy propyl )methacry I ate (HPMA), N-vinyl-2-pyrrolidone (NV P), N-isopropylacrylamide (NIPA M M), vinyl acetate (VA), acryolic acid (AA), methacrylic acid (MAA), polyethylene glycol acrylate/methacrylate (PEGA/PEG MA), polyethylene glycol diacrylate/dimethacrylate (PE GDA/PEG DMA) and others.

Another mechanism to induce sol-gel transition is a change in pH. All the pH-sensitive polymers contain pendant acidic or basic groups that either accept or release protons in response to changes in environmental pH. Such polymers have a large number of ionizable groups. A hydrogel swells if the external pH increases in case of polymers havi ng anionic groups while the converse is true in case of polymers having cationic groups. An embodiment of the present invention includes compositions of li poglycopeptides selected form the group consisti ng of Telavancin, Oritavancin and Dalbavancin which optionally include NSAIDs and polymers which gel in response to change in pH. Polymers which are pH sensitive and can be a part of the present i nvention include without any limitations polyacrylic acid (carbopol or carbomer), pseudo latex e.g. (CA P Latex) cellulose acetate phthalate latex and others. A further embodiment includes a composition of Dalbavancin or Oritavancin which optionally i nclude NSAIDs, in the liquid form having initial pH of 4.4 and undergoing coagulation with the rise in pH (7.7) due to contact with tear fluid. A change of 2.28 pH units leads to instantaneous gel-sol transition.

A further embodiment includes an oil-in-water emulsion ophthalmic or otic l iquid composition of lipoglycopeptides selected from the group consisting of Telavancin Dalbavancin and Oritavancin. The emulsifying agents which can be used in the embodiment of the present invention include without limitation medium chain triglycerides, Pemulen. The oleaginous vehicle can includes without limitation castor oil, sesame oil, flaxseed oil, soybean oil.

A nother embodi ment of the present i nventi on i ncl udes I i posomal ophthal mi c f ormul ati ons of lipoglycopeptides selected from the group consisting of Telavancin, Dalbavancin and Oritavanci n. The liposomal agents used can be selected from various ophthlamologically suitable lipids which incl ude phosphatidyl choline, cholesterol, polyethylene glycol-12- glycerol dimethyacrylate and others.

As an embodiment of the present invention are lyophilized powders which form nano- suspension on reconstitution.

Successful ocular drug delivery is a major challenge due to the unique anatomy and physiology of eye which contains various types of barriers such as different layers of cornea, sclera and reti na including blood aqueous and blood ^" retinal barriers, choroidal and conj unctival blood flow etc. These barriers cause a significant challenge for delivery of a drug al one or i n a dosage form T heref ore, sel ecti on of appropri ate exci pi ents whi ch are to be administered along with the active is an important concern. The selection of particular excipients and their concentrations is based not only on physical or chemical compatibility but also on biocompatibility with the sensitive ocular tissue.

The ophthalmic and otic compositions of the present invention can contain various pharmaceutically acceptable excipients. These include without limitation buffering agents, chelating agents, tonicity modifiers, viscosity enhancers, emulsifiers and surfactants, humectants and preservatives. i) Buffering agents Buffering agents play a vital role in maintaining pH of the compositions. Maintenance of adequate pH is necessary for stability and proper preservation of the compositions. Optimum pH of the ophthalmic solutions is also required for patient compliance and safety, particularly in case of ophthalmic products. The normal physiological pH of the tear fluid is 7.4. The pH of the compositions desired to be instilled in the eye. The compositions of the present invention include without limitation buffers such as phosphate buffers (potassium phosphate, di potassium hydrogen phosphate, potassium di hydrogen phosphate, di sodium hydrogen phosphate, sodium di hydrogen phosphate), borate buffers (potassium borate, sodium borate), citrate buffers, tartarate buffers, acetate buffers, amino acids. The pH of the ophthal mic preparations of the current invention may also be modified by using a pH modifier. pH modifiers used in the present invention include hydrochloric acid and sodium hydroxide among others. ii) Chelating agents

Chelati ng agents are used in ophthalmic compositions to enhance preservative effectiveness. While not intending to be limiting, some useful chelating agents for the purposes of thi s i nventi on are edetate salts I i ke edetate di sodi urn, edetate cal ci um di sodi um, edetate sodium, edetate tri sodium, and edetate di potassium In preferred embodiment of this invention chelating agents like E DTA are used in ophthalmic preparations when the preservative used is Benzalkonium chloride. iii) Tonicity modifiers

T he osmolarity of the lacri mal f I ui d is between 280 and 320 mOsm kg which is dependent on the number of ions dissolved in the aqueous layer of the tear fil If ophthalmic preparation is hypotonic with respect to the ophthalmic environment it will result into excessive tear secretion and irritation to the corneal epithelium The osmotic pressure of the preparati on must be same as that of normal sal i ne sol uti on. T heref ore, toni city adj usti ng agents employed in the compositions of the present invention without an intention of any limitation include sodium chloride, potassium chloride, buffer salts, dextrose, glycerine, propylene glycol, and mannitol. iv) Preservatives Preservatives are useful in avoiding microbial contamination of ophthalmic or otic dosage forms. Examples of suitable preservatives employed in the present invention include without limitation, polyquatemium-1, benzalkonium chloride, sodium perborate, thimerosal, chlorobutanol, methyl paraben, propyl paraben, phenyl ethyl alcohol, edetate disodiurn sorbic acid, or other agents known to those skilled in the art. v) V iscosity modifiers

When administered as a drop, the ophthalmic preparations are washed away by tears due to inherent reflex mechanisnri thereby dil uting the concentration of the drug. The lacrimal drai nage system responsible for this, leads the drug to nose and throat where it is absorbed into the general circulation, sometimes leading to serious systemic side effects. The otic compositions may drain to nasopharynx and upper throat through E ustachian tube. T herefore, it is an embodi ment of the present i nventi on to i ncl ude vi scosity i mparti ng agent in the formulation to prolong the retention ti me of the drug solution at the target site. Examples without limitation include methyl cellulose, hydroxyl propyl cellulose, hydroxyl propyl methyl cel lulose, polyvinyl alcohol and carbomers. vi) E mulsif iers and surfactants

Surfactants are used in ophthalmic preparations to solubilize or disperse drugs in solution or di spersi on. S urfactants al so prevent the I oss of drug to adsorpti on on the contai ner wal I s. The compositions of the present invention without limitation may include sodium lauryl sulfate, polysorbates (t eens), tyloxapol. The compositions of the present invention may include emulsifying agents. Examples of such agents without limitation include Pemulenu , medium chain triglycerides. vii) Humectants

Humectants are hygroscopic substances that keep the compositions moist. Humectants attract and retai n the moi sture i n the ai r nearby vi a absorpti on, drawi ng the water vapor i nto the preparation. Without intending any limitation, humectants employed in the compositions in the compositions of the present invention include propylene glycols, glycerol, sorbitol, maltitol, xylitol. The dosage forms of the present i nvention comprise of liquids, semi-solid and powders. The dosage forms of the present invention can be prepared by mixi ng the lipoglycopeptide antibiotics, NSAIDs (if present) and the pharmaceutically acceptable exci pi ents in suitable solvents which without any limitation can comprise water, water for injecti on (WFI), sugar solution etc. The pH is adjusted, if required. The resultant compositions are then sterilized using suitable techniques. The compositions can be freeze dried to obtain lyophilized powders.

The present invention is further described by way of the following non-limiting examples.

Table 1 : L ipoglycopeptide compositions for ophthal mic or otic use

Ingredient E 1* E 2* E 3* E4* E 5* E6* E 7* E 8* E 9*

Active** 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5

Edetate 0.015 - - 0.06 0.06 - - - - di Sodium

Disodium 0.01-5 0.01-5 - - - - - - 0.01-5 hydrogen

phosphate

Sodium -- - - - - 0.01-2 - 0.01-2 - citrate

di hydrate

Citric acid -- - - - - - - - 0.001-1

Sodium 0.01-2 0.01-2 0.01-2 0.01-2 0.01-2 0.01-2 0.01-2 - - chloride

Mannitol - - - - - - - — 0.4

Dextrose - - - - - - - 0.16 -

Carbomer - - 0.01-5 0.01-5 - - - - 0.01-5

Poloxamer - - - - - 5 - - -

X anthan - - - - - - 0.1 - - gum

H PMC - - - - - - - - 0.05

Methyl - - - - - - 0.25 - -

Cellulose

Gel Ian gum - - - - - - - 0.5 -

Polysorbate - - 0.3 - - - - - -

Tyloxapol - - - - 0.05 - - - -

Benzal koni - 0.006 0.006 0.008 0.005 - - 0.006 - urn chloride

Sodium - - — - - 0.008 0.008 - - perborate Boric acid -- -- -- -- — 0.2 -- -- --

Hydrochlor Add* Add* Add* Add* Add*

ic acid/

Sodium

Hydroxide

Water for q.s. 100 q.s. 100 q.s. q.s. 100 q.s. 100 q.s. q.s. 100 q.s. q.s. 100

Injection 100 100 100

(WFI)

Concentration in % wV

**Active is selected from a group consisting of Telavancin, Oritavancin and Dalbavancin

#Add to adj ust the pH to 7.4

T he general manuf acturi ng procedure steps for the composi ti ons from T abl e 1 i s as bel ow- i. Mix buffers (Disodium hydrogen phosphate, Sodium citrate di hydrate); buffering agents (citric acid, boric acid); tonicity modifiers (sodium chloride, mannitol, dextrose); gellants (Carbomer, xanthan gum, Hydroxypropyl methyl cellulose, poloxamer, gellan gunri methyl cellulose); surfactants (polysorbate, tyloxapol) with 50% batch quantity of WFI.

i i . Sti r the mi xture of step ( i ) to obtai n a cl ear sol uti on.

iii. Add the Active to the solution of step (ii) under continuous stirring to a obtain a clear solution

iv. Preservatives (benzalkonium chloride and sodium perborate) if present, are added to the solution of step (iii).

v. The pH of the solution of step (iv) is adj usted to 7.4 using hydrochloric acid or sodium hydroxide, if required.

vi. Filter the solution of step (v) thorough 0.2 1 m filter.

vii. The compositions of step (vi), may optional ly be freeze dried to obtai n lyophi I i zed powders.

T able 2: L ipoglycopeptide compositions with NSAID for ophthalmic or otic use

Ingredient E 1* E 2* E 3* E 4* E 5* E 6* E 7* E 8* E 9*

Active** 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5

NSAID*** 0.001-5 0.001-5 0.001-5 0.001-5 0.001-5 0.001-5 0.001-5 0.001-5 0.001-5

Edetate 0.015 — — 0.06 0.06 — — — — diSodium Disodium 0.01-5 0.01-5 - - - - - - 0.01-5 hydrogen

phosphate

Sodium -- - - - - 0.01-2 - 0.01-2 - citrate

di hydrate

Citric acid -- - - - - - - - 0.001-1

Sodium 0.01-2 0.01-2 0.01-2 0.01-2 0.01-2 0.01-2 0.01-2 - - chloride

Mannitol - - - - - - - — 0.4

Dextrose - - - - - - - 0.16 -

Carbomer - - 0.01-5 0.01-5 - - - - 0.01-5

Poloxamer - - - - - 5 - - -

X anthan - - - - - - 0.1 - - gum

HPMC - - - - - - - - 0.05

Methyl - - - - - - 0.25 - -

Cellulose

Gel Ian gum - - - - - - - 0.5 -

Polysorbate - - 0.3 - - - - - -

Tyloxapol - - - - 0.05 - - - -

Benzalkoni - 0.006 0.006 0.008 0.005 - - 0.006 - urn chloride

Sodium - - — - - 0.008 0.008 - - perborate

Boric acid - - - - — - 0.2 - -

Hydrochlor Add* Add* Add* Add* Add* - - - - ic acid/

Sodium

Hydroxide

Water for q.s. 100 q.s. 100 q.s. q.s. 100 q.s. 100 q.s. q.s. 100 q.s. q.s. 100

Injection 100 100 100

(WFI)

Concentration in % wA

**Active is selected from a group consisting of T elavancin, Oritavancin and Dalbavancin

***NSAI D is selected from Nepafenac, K etorolac tromethamine, Bromfenac, Diclofenac sodium. F lurbiprofen

^# Add to adj ust the pH to 7.4

T he general manuf acturi ng procedure steps for the composi ti ons from T abl e 2 i s as bel ow- i) Mix buffers (Disodium hydrogen phosphate, Sodium citrate di hydrate); buffering agents (citric acid, boric acid); tonicity modifiers (sodium chloride, mannitol, dextrose); gellants (Carbomer, xanthan gum, Hydroxypropyl methyl cellulose, poloxamer, gel I an gum, methyl cellulose); surfactants (polysorbate, tyloxapol) with 50% batch quantity of WFI.

i i ) Sti r the mi xture of step ( i ) to obtai n a cl ear sol uti on.

ii i) Add the Active to the solution of step (ii) under continuous stirring to a obtain a clear solution

iv) Add the NSAID under continuous stirring to the solution of step (iii).

v) Preservatives (benzalkonium chloride and sodium perborate) if present, are added to the sol uti on of step ( iv).

vi) The pH of the solution of step (iv) is adj usted to 7.4 using hydrochloric acid or sodium hydroxide, if required.

vii) Filter the solution of step (vi) thorough 0.2 ι m filter, if it s a dispersion (in case of Nepafenac) sterilization is done by radiation.

viii) The compositions of step (vii), may optionally be freeze dried to obtain lyophilized powders.

3: Nano-suspension of L ipoglycopeptide

* C oncentration i n % w/v

**Active is selected from a group consisting of T elavancin, Oritavancin and Dalbavancin.

The manufacturing procedure for powder for nano-suspension is described below- i) Prepare a concentrated solution of surfactant (Sodium Lauryl Sulfate, polysorbate) and tonicity modifying agent; if present (mannitol, glycerol 80%) for wetting. ii) Add additional quantity of Water for Injection to the sol uti on of step (i).

ii i) Add the active into the solution of step (ii) by stirring.

iv) Pass the coarsely dispersed suspension through a continuously operating homogenizer at room temperature. v) Makeup the volume of the suspension of step (iv) with WFI.

vi ) Steri I i ze the suspensi on of step ( v) by radi ati on steri I i zati on.

vii) The composition of the step (vi) is then freeze dried to get lyophilized powdi reconstitution.

Table 4: M icro-emulsion of L ipoglycopeptides

* C oncentration in % w/v

**Active is selected from a group consisting of T elavancin, Oritavancin and Dalbavancin.

The procedure for preparation of micro-emulsion is - i) Weigh and heat the components of oily phase (medium chain triglyceride, V itamin E T PGS, Pemulen, Polysorbate) with the active in a water bath.

ii) Stir the mixture of step (i) until a clear, slightly viscous sol ution is obtained. ii i) Weigh the components of aqueous phase (glycerin) and dissolve in water until a clear solution is obtained.

iv) Two phases of step (ii) and (iii) are mixed and gently stirred with a magnet v) The pH of the sol ution of step (iv) is adjusted between 5.5-7.2 using dil ute solution of hydrochloric acid or sodium hydroxide.

vi) Sterilize the composition by radiation steril ization. Table 5: Powder for L iposomal composition of L ipoglycopeptides

E xample 5a:

*Active is selected from a group consisting of T elavancin, Oritavancin and Dalbavancin.

Following is the process for making powder for liposomal formulation- i) Place 40% of the final volume of distilled water in beaker and heat it to 70 eC. ii) Add H PMC to the beaker in step (i) and stop mixing unti l reaching room temperature and it becomes a clear and homogeneous mixture.

ii i) Autoclave the solution of step (ii) and once sterile allows it to reach room temperature while sti rri ng.

iv) Place in another beaker 40% of thefinal volume of distil led water. Add and mix until completely dissolved one by one the following reagents: a) Sodium phosphate monobasic b) Sodium phosphate dibasic c) Sodium chloride d) Polysorbate 80

v) In 10% of the remaining volume of water, add the benzalkonium chloride at 50% and mix until completely incorporated. Once dissolved, add this new solution to the above solution of step (iv)

vi) Mix the sterile solution of H PMC with the other sterile solution containing the salts and the preservative benzalkonium chloride and mix until getting a clear homogeneous mixture.

vii) Dissolve the active in oily phase (PEG-12-G DM). viii) Liposome preparation entails merely mixing the lipid of step (vii) with an aqueous sol uti on of step ( i - i i i )

ix) A dd the L i posomes to this mixture and sti r duri ng 15 mi nutes with a magneti c sti rrer to obtai n a f i nal suspensi on.

x) Steri lize the dispersion of step (ix) by radiation sterilization.

xi) Freeze dry the dispersion of step (x) to get the lyophi lized powder for reconstitution.

E xample 5b:

*Active is selected from a group consisting of T elavancin,Oritavancin and Dalbavancin.

Following is the process for making powder for liposomal formulation- i) Prepare a mixture of phosphatidylcholine, cholesterol, sodium deoxycholate (12:1.7:1, w/W) and dissolve it in chloroform diethyl ether solution.

ii) Add aqueous solution of active to step (i) and sonicate for 10 minutes to form an emulsi on (w/o).

iii) Evaporate the organic solvents form emulsion of step (ii) using a rotary evaporator under vacuum at 37eC and add saccharose sol uti on (5% w/v).

iv) Sterilize the dispersion of step (iii) by radiation sterilization.

v) Freeze dry the filtrate of step (iv) to get the lyophilized powder for reconstitution.

T able 6: Powder for G el based composition of L ipoglycopeptides

Ingredient E 1* E 2*

Active** 0.5 0.5

X anthan gum 0.5 0.8

Sorbitol 25 4

Sodium edetate 0.1 0.05 Benzalkonium 0.008 —

chloride

Hydrochloric acid/ Added

Sodium Hydroxide

Water for Injection q.s. 100 q.s.

(WFI) 100

* C oncentration i n % wV

**Active is selected from a group consisting of T elavancin, Oritavancin and Dalbavancin.

The process for preparation of the gel based formulations is described below- i) Dissolve X anthan gum i n a portion of WFI.

ii) Add active, sorbitol and Sodium Edetate to the remaining amount WFI, i i i) T hen, combi ne the sol ution of step (i i) and step (i) and homogenize it. iv) Optionally, add benzalkonium chloride, to the preparation of step (iii) and mix properly.

v) Adjust the pH value to 7.4 with 1 N HCI or NaOH.

vi) Sterilize the dispersion of step (v) by radiation sterilization.

vii) Freeze dry the gel to get the lyophilized powder for reconstitution.

The invention has been described herein by reference to certain preferred embodiments. However, as obvious variations thereon will become apparent to those ski I led in the art the i nventi on must not be as I i mi ted thereto.